中国药业2017，Vol.26Issue(9)：35-37,3.DOI:10.3969/j.issn.1006-4931.2017.09.011
重组组织型纤溶酶原激活剂治疗急性缺血性脑卒中临床疗效与安全性分析
Clinical Effect and Safety of Rt-PA for Treating Acute Ischemic Stroke
李光宁 1利伟江 1李金彩 1陈伟英1
作者信息
- 1. 广东省广州市花都区人民医院神经内科,广东广州 510800
- 折叠
摘要
Abstract
Objective To analysis the effect and safety of rt-PA on acute ischemic stroke. Methods Totally 30 patients with acute is-chemic stroke(AIS) in 2016 in our hospital were treated with rt-PA. the effect and safety were evaluated. Results After 6 h of thrombolytic treatment. the NIHSS decreased obviously from (21. 32 ± 2. 64) points before treatment to (15. 87 ± 3. 25) points. after 24 h. 7d of throm-bolytic treatment. the NIHSS scores were significant decreased to (11. 14 ± 3. 12) points. (6. 45 ± 4. 35) points. The difference of NIHSS scores in before treatment. after 6 h. 24 h. 7 d of thrombolytic treatment were statistically significant ( P < 0. 05 ) . At 4. 5 h of seizure of dis-ease. 96. 67%(29/30) AIS patients′ neurological functions were basically recovered. and they culd take care of themselves. Conclusion In the treatment window of 4. 5 h. it is effective and safe to use rt-PA for treating AIS. which is worthy of clinical promotion.关键词
急性缺血性脑卒中/阿替普酶/静脉溶栓/疗效Key words
acute ischemic stroke/Alteplase/intravenous thrombolysis/clinical efficacy分类
医药卫生引用本文复制引用
李光宁,利伟江,李金彩,陈伟英..重组组织型纤溶酶原激活剂治疗急性缺血性脑卒中临床疗效与安全性分析[J].中国药业,2017,26(9):35-37,3.
